EA199800192A1 - Применение ингибиторов фосфодиестеразы (pde) в производстве лекарственных препаратов для лечения заболеваний мочевого пузыря - Google Patents

Применение ингибиторов фосфодиестеразы (pde) в производстве лекарственных препаратов для лечения заболеваний мочевого пузыря

Info

Publication number
EA199800192A1
EA199800192A1 EA199800192A EA199800192A EA199800192A1 EA 199800192 A1 EA199800192 A1 EA 199800192A1 EA 199800192 A EA199800192 A EA 199800192A EA 199800192 A EA199800192 A EA 199800192A EA 199800192 A1 EA199800192 A1 EA 199800192A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
pde
treatment
application
phosphodysterase
Prior art date
Application number
EA199800192A
Other languages
English (en)
Inventor
Вольф-Георг Форссманн
Михель Карстен Трусс
Штефан Юккерт
Кристиан Георг Штиф
Удо Йонас
Original Assignee
Вольф-Георг Форссманн
Михель Карстен Трусс
Штефан Юккерт
Кристиан Георг Штиф
Удо Йонас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вольф-Георг Форссманн, Михель Карстен Трусс, Штефан Юккерт, Кристиан Георг Штиф, Удо Йонас filed Critical Вольф-Георг Форссманн
Publication of EA199800192A1 publication Critical patent/EA199800192A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к применению ингибиторов фосфодиэстеразы I, в частности винкамина, винпоцетина (этилаповинкамина-22-оата) и/или модифицированных соединений указанных ингибиторов, обладающих ингибирующими свойствами для PDE I, а также их фармакологически совместимых солей для лечения заболеваний мочевого пузыря посредством локального и системного применения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800192A 1995-08-08 1996-08-01 Применение ингибиторов фосфодиестеразы (pde) в производстве лекарственных препаратов для лечения заболеваний мочевого пузыря EA199800192A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19529102A DE19529102A1 (de) 1995-08-08 1995-08-08 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
PCT/EP1996/003393 WO1997005876A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Publications (1)

Publication Number Publication Date
EA199800192A1 true EA199800192A1 (ru) 1999-06-24

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800192A EA199800192A1 (ru) 1995-08-08 1996-08-01 Применение ингибиторов фосфодиестеразы (pde) в производстве лекарственных препаратов для лечения заболеваний мочевого пузыря

Country Status (9)

Country Link
EP (1) EP0843553A1 (ru)
JP (1) JP2000501698A (ru)
AU (1) AU6702596A (ru)
CA (1) CA2228314A1 (ru)
DE (1) DE19529102A1 (ru)
EA (1) EA199800192A1 (ru)
HU (1) HUP0104619A3 (ru)
WO (1) WO1997005876A1 (ru)
ZA (1) ZA966698B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
WO2001017480A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one

Also Published As

Publication number Publication date
WO1997005876A1 (en) 1997-02-20
HUP0104619A3 (en) 2002-06-28
HUP0104619A2 (hu) 2002-04-29
JP2000501698A (ja) 2000-02-15
DE19529102A1 (de) 1997-02-13
AU6702596A (en) 1997-03-05
ZA966698B (en) 1998-02-09
EP0843553A1 (en) 1998-05-27
CA2228314A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
ES2133800T3 (es) Pirimido(5,4-d)pirimidinas, medicamentos que contienen estos compuestos, su uso y su procedimiento de preparacion.
EA200200208A1 (ru) Синергитическая композиция
ATE165830T1 (de) Dihydro pyrazolopyrrole
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0016693A (pt) Derivados de pirrolidina como inibidores de fosfodiesterase especìfico amp cìclico
TR199801755T2 (xx) Pirimido(5,4-D)pirimidinler, bu bile�ikleri i�eren farmas�tik maddeler.
NO995006D0 (no) Nye forbindelser
EA199800559A1 (ru) Антагонисты гонадотропин-высвобождающего фактора
EA199800564A1 (ru) Антагонисты гонадотропин-высвобождающего фактора
DK0970095T3 (da) Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
BR0014973A (pt) Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
JO2503B1 (en) Benzathiazole derivatives
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
SV2003001173A (es) 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa
NO984081L (no) Pyrimido[5,4-d]pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremtilling derav
DK1165558T3 (da) Pyrimido[6,1-a]isoquinolin-4-on-derivater
EA200100204A1 (ru) Фармацевтические агенты для лечения болезни паркинсона, ганв и микроаденом
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
EA200100792A1 (ru) Применение имидазо[1,5-a]-пиридо[3,2-e]-пиразинонов в качестве лекарственных средств
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
EA199800192A1 (ru) Применение ингибиторов фосфодиестеразы (pde) в производстве лекарственных препаратов для лечения заболеваний мочевого пузыря
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ